- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04498520
Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer
Phase I Trial of Abexinostat Combined With Palbociclib and Fulvestrant in Patients With Antiestrogen Refractory ER+, HER2- Breast Cancer and Gynecological Metastatic Tumors
Study Overview
Status
Conditions
- Anatomic Stage III Breast Cancer AJCC v8
- Anatomic Stage IIIA Breast Cancer AJCC v8
- Anatomic Stage IIIB Breast Cancer AJCC v8
- Anatomic Stage IIIC Breast Cancer AJCC v8
- Prognostic Stage III Breast Cancer AJCC v8
- Prognostic Stage IIIA Breast Cancer AJCC v8
- Prognostic Stage IIIB Breast Cancer AJCC v8
- Prognostic Stage IIIC Breast Cancer AJCC v8
- Recurrent Fallopian Tube Carcinoma
- Recurrent Ovarian Carcinoma
- Recurrent Primary Peritoneal Carcinoma
- Anatomic Stage IV Breast Cancer AJCC v8
- Prognostic Stage IV Breast Cancer AJCC v8
- Stage IV Uterine Corpus Cancer AJCC v8
- Stage IVA Uterine Corpus Cancer AJCC v8
- Stage IVB Uterine Corpus Cancer AJCC v8
- Metastatic Malignant Solid Neoplasm
- Hormone Receptor Positive Breast Carcinoma
- Metastatic Breast Carcinoma
- Refractory Breast Carcinoma
- Stage IV Fallopian Tube Cancer AJCC v8
- Stage IV Ovarian Cancer AJCC v8
- Stage IV Primary Peritoneal Cancer AJCC v8
- Stage IVA Fallopian Tube Cancer AJCC v8
- Stage IVA Ovarian Cancer AJCC v8
- Stage IVA Primary Peritoneal Cancer AJCC v8
- Stage IVB Fallopian Tube Cancer AJCC v8
- Stage IVB Ovarian Cancer AJCC v8
- Stage IVB Primary Peritoneal Cancer AJCC v8
- Metastatic Ovarian Carcinoma
- Locally Advanced Breast Carcinoma
- Metastatic Endometrioid Adenocarcinoma
- Metastatic Fallopian Tube Carcinoma
- Metastatic HER2 Negative Breast Carcinoma
- Metastatic Primary Peritoneal Carcinoma
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVES:
- To determine the safety and tolerability of abexinostat tosylate (abexinostat) and palbociclib in combination with fulvestrant.
- To determine the maximum tolerated dose (MTD) for abexinostat and palbociclib when combined with fulvestrant at standard dose.
SECONDARY OBJECTIVES:
- To describe the pharmacokinetics associated with abexinostat.
- To describe the efficacy of abexinostat and palbociclib in combination with fulvestrant in patients with antiestrogen refractory estrogen receptor positive (ER+), HER2 negative(-) breast cancer and gynecological metastatic tumors.
- To assess the clinical benefit rate (CBR) defined as complete response (CR), partial response (PR), and stable disease (SD) at 6 months and progression free survival according to Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1.
EXPLORATORY OBJECTIVES:
- To assess correlations between overall response rate (ORR), CBR at 6 months, and progression free survival (PFS) with genomic aberrations assessed as cell free tumor deoxyribonucleic acid (DNA) and histone acetylation on peripheral blood.
- To assess correlations between ORR, CBR at 6 months, and PFS endpoints and peripheral blood mononuclear cell (PBMC) histone deacetylase (HDAC) gene expression, PBMC acetylation in vivo and ex vivo.
OUTLINE: This is a dose-escalation study of abexinostat and palbociclib.
Patients receive abexinostat orally (PO) twice daily (BID) on days 1-4, 8-11, and 15-18, palbociclib PO once daily (QD) on days 1-21, and fulvestrant intramuscularly (IM) on days 1 and 15 of cycle 1 and day 1 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Patients will be followed for 90 days after completion of treatment or removal from study, or until death, whichever occurs first.
Study Type
Phase
- Phase 1
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- BREAST CANCER: Participants must have histologically confirmed hormone receptor (HR)+, HER2- locally advanced or metastatic stage IV breast cancer. HER2- should be defined as 0 or 1 by immunohistochemistry, or HER2 gene amplification by fluorescence in situ hybridization (FISH), chromogenic in situ hybridization (CISH), or in situ hybridization (ISH) performed upon the primary tumor or metastatic lesion (ration < 2 and HER2 copy < 4). Estrogen receptor (ER) and progesterone receptor (PR) expression positivity is defined as more than 5% of tumor cells nuclei positive by immunohistochemistry in the sample on testing
BREAST CANCER: Patients must have had disease progression after treatment with anti-estrogen therapy combined with Cyclin-dependent kinase 4/6 (CDK4/6) inhibitor after a minimum of at least 3 months therapy in the metastatic setting and no more than 3 prior lines of systemic therapy for metastatic breast cancer (MBC), unrestricted prior therapy in the dose escalation
- Note: Patients with breast cancer who were not previously treated with CDK4/6 inhibitors or have not tolerated full doses of prior ribociclib or palbociclib or abemaciclib are not eligible
- ENDOMETRIAL CANCER: Patients must have histologically confirmed metastatic endometrial cancer of endometrioid type
- ENDOMETRIAL CANCER: Tumors must have ER expression
ENDOMETRIAL CANCER: Patients must have received a maximum of one line of hormonal therapy for the treatment of endometrial cancer and may have received any lines of chemotherapy treatment
- Note: Mixed tumor histology is allowed if the non-endometrioid component is less than 1%. Tumor must be estrogen receptor positive
- OVARIAN, FALLOPIAN TUBE, OR PERITONEAL EPITHELIAL CANCER: Patients must have histologically confirmed recurrent or metastatic ovarian, fallopian, or peritoneal epithelial carcinoma
- OVARIAN, FALLOPIAN TUBE, OR PERITONEAL EPITHELIAL CANCER: Tumors must have ER expression
OVARIAN, FALLOPIAN TUBE, OR PERITONEAL EPITHELIAL CANCER: Patients must have received a maximum of one line of hormonal therapy for the treatment of ovarian cancer and may have received any lines of chemotherapy treatment
- Note: pure clear cell and pure mucinous ovarian carcinomas are not eligible
- ALL PATIENTS
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1
- Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension in accordance with RECIST criteria v. 1.1
- Leukocytes >= 2,500/microliter (mcL)
- Absolute neutrophil count >= 1,500/mcL
- Hemoglobin > 9 g/dl (transfusions are allowed if more than 7 days prior to enrollment)
- Platelets >= 100,000/mcL
- Total bilirubin < upper limit of normal (ULN) except for patients with Gilbert's syndrome, who may only be included if the total bilirubin is =< 3.0 x ULN or direct bilirubin =< 1.5 x ULN
- International normalized ratio (INR) =< 1.5 (unless the patient is receiving anticoagulants and the INR is within the therapeutic range of intended use for that anticoagulant within 7 days prior to the first dose of study drug)
- Aspartate transaminase (AST) < 2.5 x ULN, except for patients with liver metastasis, who are only included if the AST is < 5 x ULN
- Alanine transaminase (ALT) < 2.5 x ULN, except for patients with liver metastasis, who are only included if the ALT is < 5 x ULN
- Alkaline phosphate =< 2.5 x ULN (unless bone metastasis is present in the absence of liver metastasis, in which 3.0 x ULN would be acceptable)
- Serum creatinine =< 1.5 mg/dl
- Patients must be recovered from the effects of any prior surgery, radiotherapy, or other antineoplastic therapy
- Patients may have received fulvestrant if the duration of response was more than 3 months
- Ability to understand a written informed consent document, and the willingness to sign it
- All female patients must be post-menopausal or rendered postmenopausal during the therapy
- All male patients must be surgically sterile or agree to abstain from sperm donation and use both, a highly effective contraception with child bearing potential female partners (implants, injectables, combined oral contraceptives, some intrauterine device (IUD)s, sexual abstinence) and a barrier method (e.g., condoms, cervical rings, cervical condoms, sponge) during participation in the study and for 90 days after the last dose of study drug
- Must be able to swallow pills
Exclusion Criteria:
- Patient with symptomatic visceral disease or any disease burden that renders the patient ineligible for endocrine therapy per the investigator's best judgment
- Patients who have had chemotherapy or radiotherapy within 2 weeks prior to entering the study or those who have not recovered from adverse event to grade 1 or less from agents administered more than 2 weeks earlier
- Patient has received treatment with any investigational drug within 21 days prior to study treatment administration. For classes of investigational agents that are not known to have prolonged toxicities, the washout time may be decreased to 14 days at the discretion of the principal investigator
- Patients may not have any known intolerability to any of the involved agents or established cytopenias to CDK4/6 inhibitors that require dose modifications or dose delays of greater than 2 weeks
- Patient with a known hypersensitivity to any of the excipients of palbociclib, abexinostat, or fulvestrant, including to peanut and soy
- Patient has a concurrent malignancy or malignancy within 3 years of study entry, with the exception of adequately treated, basal or squamous cell skin carcinoma, nonmelanomatous skin cancer or curatively resected cervical cancer
- Patient who has a history of untreated brain, or leptomeningeal, metastases (central nervous system (CNS) imaging is not required before study entry unless there is a clinical suspicion of CNS involvement)
Participants with previously treated brain metastases may participate, provided:
- They are stable (without evidence of progression by imaging for at least four weeks and any neurologic symptoms have returned to baseline)
- They have no evidence of new or enlarging brain metastases (confirmed by imaging within 28 days of the first dose of study drug)
- They are not using steroids for at least 7 days before the first dose of study drug
Have isolated lesions that were treated with localized radiation therapy
- This exception does not include leptomeningeal metastases, which is excluded regardless of clinical stability
- Patient must not have been previously treated with histone deacetylase inhibitor (HDACi), with the exception of low dose of divalproex sodium (Depakote) or valproic acid
- Patient has any medical, psychiatric or social condition, which in the opinion of the investigator, places the patient at an unacceptably high risk for toxicities or affects compliance to study procedures
- Patient has impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of the study drugs (e.g., uncontrolled ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection)
Patient is currently receiving or has received systemic therapeutic doses of corticosteroids =< 2 weeks prior to starting study drug, or has not fully recovered from side effects of such treatment
- Note: The following uses of corticosteroids are permitted: single doses, topical applications (e.g., for rash), inhaled sprays (e.g., for obstructive airways diseases), eye drops or local injections (e.g., intra-articular)
- Patient has known clinically significant, uncontrolled heart disease and/or cardiac repolarization abnormality
Patient is currently receiving any of the following substances and cannot be discontinued 30 days prior to cycle 1 day 1:
- Concomitant medications, herbal supplements, and/or fruits (e.g. grapefruit, pummelos, star fruit, Seville oranges) and their juices that are strong inducers or inhibitors of CYP3A4/5,
- Medications that have a narrow therapeutic window and are predominantly metabolized through CYP3A4/5 and CYP2D6 substrates
Has uncontrolled intercurrent illness including, but not limited to:
- Uncontrolled infection
- Disseminated intravascular coagulation
- Psychiatric illness/social situations that would limit compliance with study requirements
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment (abexinostat tosylate, palbociclib, fulvestrant)
Patients receive abexinostat PO BID on days 1-4, 8-11, and 15-18, palbociclib PO QD on days 1-21, and fulvestrant IM on days 1 and 15 of cycle 1 and day 1 of subsequent cycles.
Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
|
Given PO
Other Names:
Given IM
Other Names:
Given PO
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Dose limiting toxicities (DLTs)
Time Frame: At the end of Cycle 1 (each cycle is 28 days)
|
An occurrence of any of the protocol specified toxicities occurring during cycle 1: (1) Hematologic - Grade 4 neutropenia lasting > 5 consecutive days, Grade 3/4 febrile neutropenia, Grade 4 thrombocytopenia lasting >=7 days, or Grade 3 or 4 thrombocytopenia w/ clinically significant bleeding or requirement for platelet transfusion, (2) Non-hematologic: Any adverse event (AE) >= Grade 3, with the exceptions of Grade 3 nausea, vomiting, diarrhea, clinically insignificant laboratory abnormality, or fatigue resolving to Grade <=2 w/in 72 hours (3) Any AE that results in delay in administration of abexinostat or palbociclib of less than 75% and a delay of more than 7 days before starting cycle 2 unless the AE can be clearly attributed to an extraneous cause.
DLTs are classified according to Medical Dictionary for Regulatory Activities (MedDRA) version 20 and graded for severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE).
|
At the end of Cycle 1 (each cycle is 28 days)
|
Maximum tolerated dose (MTD)
Time Frame: At the end of Cycle 1 (each cycle is 28 days)
|
Defined as the dose at which fewer than one-third of participants experience a DLT or the highest dose at which no more than one instance of DLT is observed among 6 participants treated.
|
At the end of Cycle 1 (each cycle is 28 days)
|
Incidence of treatment-related adverse events (AE)
Time Frame: From initiation of study treatment until 30 days after completion of study treatment, up to 1 year
|
Adverse events will be classified using MedDRA version 20.0 and graded for severity using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0.
Will be summarized with descriptive statistics.
|
From initiation of study treatment until 30 days after completion of study treatment, up to 1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Abexinostat: Maximum concentration (Cmax)
Time Frame: Cycle 1, Days 1 and 11; Cycle 2, Day 11 (each cycle is 28 days)
|
Serum samples will be collected in order to obtain the Cmax of abexinostat over the course of 2 cycles under the following schedule: Pre-dose, immediately post-admin, 4 hrs (+/- 30 min) post-start of drug administration, and after completion of study drug administration on Cycle 1, Day 11 and Cycle 2, Day 11
|
Cycle 1, Days 1 and 11; Cycle 2, Day 11 (each cycle is 28 days)
|
Abexinostat: Trough concentration (Ctrough)
Time Frame: Cycle 1, Days 1 and 11; Cycle 2, Day 11 (each cycle is 28 days)
|
Serum samples will be collected in order to obtain the Ctrough of abexinostat over the course of 2 cycles under the following schedule: Pre-dose, immediately post-admin, 4 hrs (+/- 30 min) post-start of drug administration, and after completion of study drug administration on Cycle 1, Day 11 and Cycle 2, Day 11
|
Cycle 1, Days 1 and 11; Cycle 2, Day 11 (each cycle is 28 days)
|
Objective response rates (ORR)
Time Frame: Up to 1 year
|
An objective response is defined as Complete Response (CR), Partial Response (PR), assessed by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 from initiation of study therapy until disease progression or study discontinuation, .
ORR will be estimated using an exact method based on the binomial distribution (Clopper-Pearson interval) with a 90% confidence interval.
|
Up to 1 year
|
Clinical benefit rate (CBR)
Time Frame: Up to 6 months
|
CBR is defined as the proportion of participants who displayed a clinical benefit (CR, PR, or Stable Disease (SD)) per RECIST v 1.1 and without disease progression at 6 months after initiation of study therapy.
|
Up to 6 months
|
Median progression-free survival (PFS)
Time Frame: Up to 1 year
|
PFS will be determined according to RECIST v 1.1 and measured as the time from first objective response after initiation of study therapy until the time of progression or death, which ever occurs first .
Will be estimated using Kaplan-Meier analysis.
|
Up to 1 year
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Pathologic Processes
- Skin Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Adenocarcinoma
- Neoplasms, Glandular and Epithelial
- Peritoneal Diseases
- Uterine Neoplasms
- Genital Neoplasms, Female
- Endocrine System Diseases
- Disease Attributes
- Ovarian Diseases
- Adnexal Diseases
- Gonadal Disorders
- Digestive System Neoplasms
- Endocrine Gland Neoplasms
- Breast Diseases
- Fallopian Tube Diseases
- Abdominal Neoplasms
- Endometrial Neoplasms
- Breast Neoplasms
- Carcinoma
- Recurrence
- Ovarian Neoplasms
- Fallopian Tube Neoplasms
- Peritoneal Neoplasms
- Carcinoma, Ovarian Epithelial
- Carcinoma, Endometrioid
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Protein Kinase Inhibitors
- Hormone Antagonists
- Estrogen Antagonists
- Estrogen Receptor Antagonists
- Histone Deacetylase Inhibitors
- Fulvestrant
- Palbociclib
- Abexinostat
Other Study ID Numbers
- 20953
- NCI-2020-05026 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Anatomic Stage III Breast Cancer AJCC v8
-
Mayo ClinicNational Cancer Institute (NCI)Active, not recruitingAnatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic... and other conditionsUnited States
-
M.D. Anderson Cancer CenterActive, not recruitingAnatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingAnatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic... and other conditionsUnited States
-
M.D. Anderson Cancer CenterActive, not recruitingAnatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic... and other conditionsUnited States
-
University of WashingtonNational Cancer Institute (NCI); University of Wisconsin, MadisonRecruitingAnatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC... and other conditionsUnited States
-
Ohio State University Comprehensive Cancer CenterRecruitingAnatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic... and other conditionsUnited States
-
Ohio State University Comprehensive Cancer CenterNational Cancer Institute (NCI)RecruitingA Quality of Life Intervention (Y-AMBIENT) for Young African American With Stage I-III Breast CancerAnatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingAnatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Anatomic Stage IIIC Breast Cancer AJCC... and other conditionsUnited States
-
Emory UniversityNational Cancer Institute (NCI); National Institutes of Health (NIH); NRG OncologyActive, not recruitingAnatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic... and other conditionsUnited States
-
Mayo ClinicNational Cancer Institute (NCI)TerminatedAnatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic... and other conditionsUnited States
Clinical Trials on Palbociclib
-
PfizerCompleted
-
PfizerCompleted
-
MegalabsNot yet recruiting
-
PfizerCompletedHealthyUnited States
-
Memorial Sloan Kettering Cancer CenterPfizerCompletedSarcoma | LiposarcomaUnited States
-
PfizerCompletedHealthy, Hepatic InsufficiencyUnited States
-
PfizerCompleted
-
PfizerCompleted